Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 14,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $24.72, for a total transaction of $346,080.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50.
• On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.81, for a total transaction of $51,382.50.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $17.30 on Thursday. The company has a market capitalization of $712.76 million, a P/E ratio of -7.90 and a beta of 1.06. The company has a fifty day moving average of $16.98 and a 200 day moving average of $14.31. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. Analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently bought and sold shares of ELVN. Barclays PLC purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $158,000. Bank of New York Mellon Corp purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $335,000. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $36,000. Citigroup Inc. purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $247,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $217,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.